Review
doi: 10.1007/s11899-013-0184-z.
Genetic basis of MPN: Beyond JAK2-V617F
Affiliations
- PMID: 24190690
- DOI: 10.1007/s11899-013-0184-z
Item in Clipboard
Review
Genetic basis of MPN: Beyond JAK2-V617F
Curr Hematol Malig Rep.
2013 Dec.
Abstract
The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by genetic alterations, often affecting cytokine signaling and gene expression. This review outlines somatic changes discovered in myeloproliferative neoplasms and how these genetic aberrations influence the pathogenesis of myeloproliferative neoplasms. Furthermore, genetic responses to drug treatments in myeloproliferative neoplasms are discussed.
Similar articles
-
Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.Diagn Mol Pathol. 2012 Sep;21(3):176-83. doi: 10.1097/PDM.0b013e318246975e. Diagn Mol Pathol. 2012. PMID: 22847163
-
[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].Orv Hetil. 2006 Nov 12;147(45):2175-9. Orv Hetil. 2006. PMID: 17402211 Hungarian.
-
Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.Pathologe. 2016 Nov;37(Suppl 2):175-179. doi: 10.1007/s00292-016-0240-2. Pathologe. 2016. PMID: 27796499 Review. English.
-
[JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].Korean J Lab Med. 2010 Dec;30(6):567-74. doi: 10.3343/kjlm.2010.30.6.567. Korean J Lab Med. 2010. PMID: 21157140 Korean.
-
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Acta Haematol. 2015. PMID: 25116092 Review.
Cited by
-
Epigenetics in Myeloproliferative Neoplasms.J Cell Mol Med. 2017 Sep;21(9):1660-1667. doi: 10.1111/jcmm.13095. Epub 2017 Jul 4. J Cell Mol Med. 2017. PMID: 28677265 Free PMC article. Review.
-
Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.Expert Opin Ther Targets. 2018 Jan;22(1):45-57. doi: 10.1080/14728222.2018.1406924. Epub 2017 Nov 24. Expert Opin Ther Targets. 2018. PMID: 29148847 Free PMC article. Review.
-
Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.Stem Cell Investig. 2016 Feb 26;3:5. doi: 10.3978/j.issn.2306-9759.2016.02.03. eCollection 2016. Stem Cell Investig. 2016. PMID: 27358897 Free PMC article. Review.
-
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.Blood Cancer J. 2015 Nov 13;5(11):e366. doi: 10.1038/bcj.2015.95. Blood Cancer J. 2015. PMID: 26565403 Free PMC article. Review.
-
The Role of Inflammation and Inflammasome in Myeloproliferative Disease.J Clin Med. 2020 Jul 22;9(8):2334. doi: 10.3390/jcm9082334. J Clin Med. 2020. PMID: 32707883 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
